Company News
Suven Life Sciences Masupirdine Phase 3 Trial Continues Unchanged
Suven Life Sciences announced positive DSMB safety review and interim analysis for its global Phase 3 study of Masupirdine in Alzheimer's disease agitation.
The independent DSMB recommended no modific
